Pancreatic Ductal Adenocarcinoma tumor transcriptome (PDAC transcriptome)

The Pancreatic Ductal Adenocarcinoma (PDAC) tumor transcriptome represents the complete set of RNA transcripts, including messenger RNA (mRNA), microRNA (miRNA), and long non-coding RNA (lncRNA), expressed within PDAC tumor cells and their surrounding microenvironment (Bailey et al., Nature 2016). It is not a single therapeutic target but rather a comprehensive molecular snapshot used to understand the biological heterogeneity of the disease and to identify specific druggable drivers (Moffitt et al., Nature Genetics 2015). Research into the PDAC transcriptome has led to the identification of distinct molecular subtypes, such as 'Classical' and 'Basal-like,' which correlate with different clinical outcomes and therapeutic responses (Collisson et al., Nature Medicine 2011). While individual components of the transcriptome, such as specific oncogenic mRNAs or regulatory RNAs, can be targeted by drugs like antisense oligonucleotides or small molecules, the transcriptome as a whole serves as a diagnostic and prognostic tool (NIH/NCI). Understanding the transcriptome is crucial for precision medicine in pancreatic cancer, as it helps in identifying biomarkers for patient stratification and monitoring treatment efficacy (PubMed: 32015477). Consequently, the transcriptome provides the foundational data necessary for the development of personalized therapeutic strategies in one of the most lethal forms of cancer.

Other names

PDAC gene expression profilePancreatic cancer RNA-seq dataPancreatic ductal adenocarcinoma expression signaturePDAC transcriptomic landscape

Not applicable as the transcriptome is a collection of RNA transcripts rather than a single druggable protein or receptor.